Related references
Note: Only part of the references are listed.A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer
Laura Vidal et al.
CLINICAL CANCER RESEARCH (2008)
Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity
Robin J. Prestwich et al.
CLINICAL CANCER RESEARCH (2008)
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus
Jian Qiao et al.
CLINICAL CANCER RESEARCH (2008)
Reovirus: Viral therapy for cancer 'as nature intended'
C. Comins et al.
CLINICAL ONCOLOGY (2008)
Oncolytic viruses: a novel form of immunotherapy
Robin J. Prestwich et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery
S. H. Thorne et al.
GENE THERAPY (2008)
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial
C. L. White et al.
GENE THERAPY (2008)
Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma
F. Errington et al.
GENE THERAPY (2008)
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors
J. Qiao et al.
GENE THERAPY (2008)
Reovirus activates human dendritic cells to promote innate antitumor immunity
Fiona Errington et al.
JOURNAL OF IMMUNOLOGY (2008)
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naive cytotoxic priming and anti-tumour therapy
Alison Merrick et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy
Jian Qiao et al.
NATURE MEDICINE (2008)
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus
Rosa Maria Diaz et al.
CANCER RESEARCH (2007)
Systemic efficacy with oncolytic virus therapeutics: Clinical proof-of-concept and future directions
Ta-Chiang Liu et al.
CANCER RESEARCH (2007)
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity
Anthony T. Power et al.
MOLECULAR THERAPY (2007)
Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy
Ianko D. Iankov et al.
MOLECULAR THERAPY (2007)
Adenovirus type 5 interactions with human blood cells may compromise systemic delivery
Mark Lyons et al.
MOLECULAR THERAPY (2006)
Current strategies and future directions for eluding adenoviral vector immunity
Dinesh S. Bangari et al.
CURRENT GENE THERAPY (2006)
Synergistic antitumor effects of immune cell-viral biotherapy
SH Thorne et al.
SCIENCE (2006)
Oncolytic viral therapies - the clinical experience
M Aghi et al.
ONCOGENE (2005)
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells
C Cole et al.
NATURE MEDICINE (2005)
Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation
J Huang et al.
CANCER RESEARCH (2005)
Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee
JH Tai et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus
NK Green et al.
GENE THERAPY (2004)
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells
S Sivori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Induced recruitment of NK cells to lymph nodes provides IFN-γ for TH1 priming
A Martín-Fontecha et al.
NATURE IMMUNOLOGY (2004)
Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model
V Tsai et al.
CLINICAL CANCER RESEARCH (2004)
Cell surface activation of the alternative complement pathway by the fusion protein of measles virus
P Devaux et al.
JOURNAL OF GENERAL VIROLOGY (2004)
PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver
MA Croyle et al.
HUMAN GENE THERAPY (2002)
The complement response against an oncolytic virus is species-specific in its activation pathways
H Wakimoto et al.
MOLECULAR THERAPY (2002)
Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
Y Chen et al.
HUMAN GENE THERAPY (2000)
Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney
XH Ye et al.
HUMAN GENE THERAPY (2000)
Share Paper
